MRK - Merck & Co., Inc.
NYSE
->
Healthcare
->
Drug Manufacturers—General
Kenilworth,
United States
Type: Equity
MRK price evolution
MRK
| (in millions $) | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 | 30 Oct 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $11304 | $5579 | $6841 | $8605 |
| Short term investments | $50 | $40 | $252 | $168 |
| Net receivables | $11642 | $12110 | $10349 | $10394 |
| Inventory | $6469 | $6510 | $6358 | $6131 |
| Total current assets | $38205 | $31445 | $32168 | $31954 |
| Long term investments | $357 | $280 | $252 | $1306 |
| Property, plant & equipment | $23221 | $23045 | $23051 | $22526 |
| Goodwill & intangible assets | $38145 | $38753 | $39208 | $40382 |
| Total noncurrent assets | $74425 | $74404 | $74507 | $74773 |
| Total investments | $407 | $320 | $504 | $1474 |
| Total assets | $112630 | $105849 | $106675 | $106727 |
| Current liabilities | ||||
| Accounts payable | $3519 | $3514 | $3922 | $3509 |
| Deferred revenue | ||||
| Short long term debt | $3071 | $3077 | $1372 | $887 |
| Total current liabilities | $26060 | $25099 | $25694 | $23094 |
| Long term debt | $34717 | $31142 | $33683 | $33972 |
| Total noncurrent liabilities | $42922 | $40326 | $43346 | $42333 |
| Total debt | $37788 | $34219 | $35055 | $34859 |
| Total liabilities | $68982 | $65485 | $69040 | $65427 |
| Shareholders' equity | ||||
| Retained earnings | $60187 | $56697 | $53895 | $57082 |
| Other shareholder equity | -$5361 | -$5274 | -$5161 | -$4916 |
| Total shareholder equity | $43582 | $40364 | $37581 | $41246 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $6841 | $12694 | $8096 | $8062 |
| Short term investments | $252 | $498 | ||
| Net receivables | $10349 | $9450 | $9230 | $7851 |
| Inventory | $6358 | $5911 | $5953 | $6310 |
| Total current assets | $32168 | $35722 | $30266 | $27764 |
| Long term investments | $252 | $1015 | $370 | $785 |
| Property, plant & equipment | $23051 | $22768 | $19279 | $17986 |
| Goodwill & intangible assets | $39208 | $41473 | $44197 | $34842 |
| Total noncurrent assets | $74507 | $73438 | $75428 | $63824 |
| Total investments | $504 | $1513 | $370 | $785 |
| Total assets | $106675 | $109160 | $105694 | $91588 |
| Current liabilities | ||||
| Accounts payable | $3922 | $4264 | $4609 | $4594 |
| Deferred revenue | ||||
| Short long term debt | $1372 | $1946 | $2412 | $6431 |
| Total current liabilities | $25694 | $24239 | $23872 | $27327 |
| Long term debt | $33683 | $28745 | $30690 | $25360 |
| Total noncurrent liabilities | $43346 | $38863 | $43565 | $38857 |
| Total debt | $35055 | $30691 | $33102 | $31791 |
| Total liabilities | $69040 | $63169 | $67437 | $66184 |
| Shareholders' equity | ||||
| Retained earnings | $53895 | $61081 | $53696 | $47362 |
| Other shareholder equity | -$5161 | -$4768 | -$4429 | -$6634 |
| Total shareholder equity | $37581 | $45991 | $38184 | $25317 |
| (in millions $) | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 | 30 Oct 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $16112 | $14630 | $15962 | |
| Cost of revenue | ||||
| Gross Profit | $13039 | $11290 | $12283 | |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $6164 | $11589 | $5759 | |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $545 | -$821 | $870 | |
| Interest expense | $49 | $61 | -$17 | |
| Net income | ||||
| Net income | $5455 | -$1226 | $4745 | |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Dec 2022 | 31 Jan 2022 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $60115 | $59283 | $47994 | |
| Cost of revenue | $17411 | $15485 | ||
| Gross Profit | $46218 | $41872 | $32509 | |
| Operating activities | ||||
| Research & development | $13548 | $13558 | ||
| Selling, general & administrative | $10042 | $10468 | ||
| Total operating expenses | $40007 | $23927 | $24604 | |
| Operating income | $17945 | $7905 | ||
| Income from continuing operations | ||||
| EBIT | $16437 | $8776 | ||
| Income tax expense | $1512 | $1918 | $1709 | |
| Interest expense | $279 | |||
| Net income | ||||
| Net income | $365 | $14519 | $7067 | |
| Income (for common shares) | $14519 | $7067 | ||
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Net income | $5455 | $4762 | -$1226 | $4745 |
| Operating activities | ||||
| Depreciation | $1132 | $984 | $964 | $1014 |
| Business acquisitions & disposals | $1145 | |||
| Stock-based compensation | $203 | $176 | $167 | $164 |
| Total cash flows from operations | $5637 | $3090 | $246 | $7717 |
| Investing activities | ||||
| Capital expenditures | -$791 | -$861 | -$989 | -$902 |
| Investments | $11 | $245 | -$82 | $587 |
| Total cash flows from investing | -$1069 | -$1376 | $53 | -$334 |
| Financing activities | ||||
| Dividends paid | -$1986 | -$1950 | -$1852 | -$1855 |
| Sale and purchase of stock | -$178 | -$35 | -$387 | -$459 |
| Net borrowings | $3600 | -$751 | -$3 | -$1945 |
| Total cash flows from financing | $1216 | -$2814 | -$2245 | -$4269 |
| Effect of exchange rate | -$82 | -$138 | $186 | -$157 |
| Change in cash and equivalents | $5702 | -$1238 | -$1760 | $2957 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $365 | $14519 | $13049 | $7067 |
| Operating activities | ||||
| Depreciation | $3872 | $3909 | $3214 | $3625 |
| Business acquisitions & disposals | -$10887 | -$121 | -$12907 | -$7606 |
| Stock-based compensation | $645 | $541 | $479 | $475 |
| Total cash flows from operations | $13006 | $19095 | $14109 | $10253 |
| Investing activities | ||||
| Capital expenditures | -$3863 | -$4388 | -$4448 | -$4684 |
| Investments | $703 | -$483 | $1025 | $2717 |
| Total cash flows from investing | -$14083 | -$4960 | -$16555 | -$9443 |
| Financing activities | ||||
| Dividends paid | -$7445 | -$7012 | -$6610 | -$6215 |
| Sale and purchase of stock | -$1221 | $384 | -$638 | -$1192 |
| Net borrowings | $4184 | -$2251 | $1631 | $5011 |
| Total cash flows from financing | -$4810 | -$9119 | $2593 | -$2832 |
| Effect of exchange rate | $23 | -$410 | -$133 | $253 |
| Change in cash and equivalents | -$5864 | $4606 | $14 | -$1769 |
News
Fundamentals
| Market cap | $298.80B |
|---|---|
| Enterprise value | $325.28B |
| Shares outstanding | 2.54B |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | 7.16% |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 6.11 |
| Book/Share | 19.30 |
| Cash/Share | 4.46 |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 1.84 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.47 |
| Quick ratio | 1.22 |